Cardiology Insight Report
A peer insight report on female-specific risk enhancers, INOCA and microvascular disease, diagnostic bias, access to advanced testing, treatment intensity, cardio-obstetric integration and evidence confidence.
Audience: Cardiologists
Countries: 6
Survey records: 77
-Hero findings
– Quick Read — Key Findings
The full report tracks the disconnect between clinical awareness, diagnostic access, treatment intensity, women-specific evidence and system integration.
Cardiovascular disease in women includes risk and presentation patterns that are not always captured by a generic obstructive-coronary model. Pregnancy-related hypertension and preeclampsia carry implications beyond pregnancy, while INOCA and coronary microvascular dysfunction are important causes of symptoms in women.
In March 2026, the American Heart Association again emphasized the cardiovascular significance of preeclampsia and the importance of continued risk awareness. AHA resources on INOCA also highlight microvascular dysfunction and inconsistent diagnostic pathways as major women’s health issues.
The MDForLives survey suggests that cardiologists increasingly recognize these distinctions, but the systems around diagnosis, payer approval, treatment escalation and cross-specialty referral do not always move at the same pace.
Selected external context: American Heart Association, Preeclampsia, High Blood Pressure and Maternal Health, March 2026; American Heart Association, Coronary Microvascular Disease; American Heart Association, INOCA Is a Women’s Health Crisis Hiding in Plain Sight
MDForLives Research Interpretation
54.7% systematically screen reproductive and obstetric risk enhancers and may escalate low-to-intermediate risk patients to calcium scoring or CCTA. 28.3% use these factors selectively, while 17.0% rarely do because standard EHR risk engines remain the primary driver.
What the pattern suggests: The majority report an active sex-specific risk lens, but the workflow still depends partly on clinician memory and selective history-taking rather than a universally embedded digital pathway.
Why it matters: When risk factors are not structurally captured, consistency can vary by clinician, setting and how obviously the traditional score appears discordant.
66.0% pursue advanced physiology for coronary microvascular dysfunction, 28.3% initiate empiric cardioprotective or anti-anginal therapy without further advanced testing, and 5.7% de-escalate toward non-cardiac explanations.
What the pattern suggests: Most respondents recognize that non-obstructive epicardial disease does not exclude a clinically meaningful ischemic mechanism.
Why it matters: INOCA pathways depend on access to specialized imaging or functional testing, making diagnostic recognition only the first step.
40.4% say they constantly observe female acute ischemia initially misattributed to anxiety or panic, 51.9% see it occasionally, and 7.7% rarely observe it.
What the pattern suggests: The most striking finding is not that bias exists in isolated cases. It is that more than nine in ten respondents still see it at least occasionally.
Why it matters: Early symptom framing influences testing, triage intensity and time to definitive treatment, especially in presentations that do not fit the classic chest-pain narrative.
46.2% describe prior authorization for advanced microvascular imaging as severe, 48.1% as moderate, and only 5.8% as low.
What the pattern suggests: The survey shows a near-universal access burden exactly where the diagnostic pathway becomes more specialized.
Why it matters: A clinician can recognize INOCA and still be unable to confirm the mechanism promptly if PET, perfusion MRI or functional testing requires prolonged appeals or coding work.
59.6% identify provider hesitancy as the primary driver of lower GDMT titration in women, compared with 30.8% who emphasize biological intolerance and 9.6% who point to follow-up fractures. Separately, 40.4% say underrepresentation of women in major trials creates high impact on confidence when applying guideline recommendations.
What the pattern suggests: The responses locate the care gap in two places at once: clinician behavior and the evidence base that informs that behavior.
Why it matters: Closing an outcomes gap requires both stronger representation and consistent application of proven therapy, rather than assuming one problem can substitute for the other.
28.8% report seamless protocol-driven cardio-obstetric teams, 63.5% describe segmented referrals that occur reactively after decompensation, and 7.7% report no structured bridge.
What the pattern suggests: The dominant model connects specialties after risk becomes clinically obvious rather than building automatic co-management around known high-risk states.
Why it matters: Pregnancy-related cardiovascular risk is longitudinal. A fragmented handoff can lose the opportunity to translate obstetric history into future cardiovascular prevention and monitoring.
What is the single most critical change Cardiology must make, whether in diagnostic tech, electronic medical records, or clinical trials, to finally close the outcomes gap for women with cardiovascular disease?
Several responses called for sex-specific diagnostic and treatment pathways, guideline thresholds or risk scores embedded directly into clinical workflows and EHRs.
Multiple cardiologists asked for greater or one-to-one female representation in clinical studies so efficacy, safety and thresholds are not inferred from predominantly male cohorts.
Respondents raised the need to clarify whether normal ranges, disease mechanisms and treatment thresholds should differ by sex.
Some responses emphasized recognizing cardiovascular disease in women with the same seriousness as in men, changing clinical culture and improving early detection.
A minority said no single change was needed, no change was necessary, or the identified gaps were too multiple to reduce to one intervention.
Interpretation note: These themes are qualitative and directional. They summarize recurring ideas in substantive open-ended responses and are not presented as weighted percentages.
The survey does not show a cardiology workforce unaware of women’s cardiovascular disease. It shows a workforce trying to apply a more sex-specific clinical model inside systems that remain partly generic. Recognition of reproductive risk, INOCA and SCAD is increasingly visible, yet payer rules, treatment behavior, trial representation and referral infrastructure still create friction. The next step is therefore implementation: making women-specific risk and pathways routine enough that they no longer depend on an individual clinician remembering to compensate for the system.
Clinical context sources: American Heart Association: Coronary Microvascular Disease · American Heart Association: Spontaneous Coronary Artery Dissection · AHA: Adverse Pregnancy Outcomes and Cardiovascular Disease Risk · AHA: Cardiovascular Considerations in Pregnancy. These FAQs provide general educational context and do not replace specialty guidance or patient-specific clinical judgment.
Direct answers to the questions healthcare professionals are most likely to ask about these findings.
